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 Chapter 14 
 Role of Central Serotonin Receptors 
in Nicotine Addiction 
 Massimo  Pierucci ,  Stephanie  Chambers ,  Lucy  Partridge , 
 Philippe  De Deurwaerdère , and  Giuseppe  Di Giovanni 
 Abstract  Regulation of normal or abnormal behaviour is critically controlled by 
the central serotonergic systems. Recent evidence has suggested that serotonin 
(5-HT) neurotransmission dysfunction contributes to a variety of pathological con-
ditions, including depression, anxiety, schizophrenia and Parkinson’s disorders. 
There is also a great amount of evidence indicating that 5-HT signalling may affect 
the reinforcing properties of drugs of abuse by the interaction and modulation of 
dopamine (DA) function. This chapter is focused on one of the more addictive 
drugs, nicotine. It is widely recognised that the effects of nicotine are strongly asso-
ciated with the stimulatory action it exhibits on mesolimbic DAergic function. 
We outline the role of 5-HT and its plethora of receptors, focusing on 5-HT 2 sub-
types with relation to their involvement in the neurobiology of nicotine addiction. 
We also explore the novel pharmacological approaches using 5-HT agents for the 
treatment of nicotine dependence. Compelling evidence shows that 5-HT 2C receptor 
agonists may be possible therapeutic targets for smoking cessation, although further 
investigation is required. 
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1  Introduction 
 There are a large number of scientifi c publications on serotonin (5-HT)-containing 
neurons in the brain and their role in normal and pathological behaviour [ 1 ,  2 ]. 
Disturbances in 5-HT function have been linked to many psychiatric and behavioural 
conditions, particularly anxiety and mood disorders [ 3 ]. This is not surprising, due to 
the complexity of 5-HT function, as it has a multitude of receptors and widespread 
5-HT neuronal innervation and is coupled with diverse signalling pathways [ 4 ,  5 ]. 
 Rather than exhibiting direct effects on cell bodies, the effects of 5-HT are usually 
indirect, involving the modulation of complex neuronal circuitry. This modulation 
is generally subtle as it is dependent on a number of other neurotransmitter baseline 
activities and their activation. The increased availability of 5-HT receptor knockout 
mice (KO) and molecular understanding of the 5-HT receptors have encouraged a 
great amount of new research in recent years [ 5 ,  6 ]. 
 Dysfunction of 5-HT neurotransmission contributes to the pathophysiology of a 
variety of neuropsychiatric disorders such as schizophrenia, depression and drug 
abuse [ 2 ,  7 ,  8 ]. Therefore, developing selective and specifi c pharmacological agents 
for 5-HT receptor subtypes has given researchers the opportunity to gain insight 
into the roles these receptors play in various disorders of the brain and clinicians’ 
new therapies with better effi cacy and fewer side effects [ 9 – 13 ]. 
 This chapter focuses on the functional role of 5-HT and its receptors in nicotine 
addiction. It reviews the anatomy of the 5-HT system and explores the distribution 
of 5-HT receptors, and the physiological and pharmacological aspects of these 
receptors in the central nervous system (CNS). Previously published experimental 
data is reviewed showing the relationship between agents specifi cally targeted to 
5-HT 2 receptors and the effect of nicotine. Consideration of the potential use of 
these agents for treatment of cessation of tobacco smoking and subsequently nico-
tine addiction is also included. 
2  Serotonergic Systems 
 5-HT has been suggested to have both excitatory and inhibitory roles in the nervous 
system; therefore there is great diffi culty in elucidating the precise nature of modula-
tion [ 14 ]. The reason for this diffi culty in classifi cation may be due to the number of 
different roles exhibited by the 5-HT receptor subtypes in association with different 
neurotransmitter systems [ 14 – 16 ]. Due to the signifi cance of 5-HT receptor control 
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on dopamine (DA) activity and the relationship between this and pathophysiology of 
specifi c DA-related diseases such as schizophrenia, depression, Parkinson’s disease 
(PD) and drug abuse, this area has received a great amount of attention [ 17 ]. 
 The distribution of 5-HT in organisms gives rise to the description of two 5-HT 
subsystems, those being central and peripheral [ 18 ]. 5-HT is found in many  different 
tissues such as the heart, lungs, blood vessels, platelets and pancreatic tissue. 
The amount of 5-HT present in the CNS is relatively low. The peripheral subsystem 
contains most of the 5-HT (90 %), which is around 10 mg in the human body, and 
is found mainly in mucosal enterochromaffi n cells of the gastrointestinal (GI) tract 
[ 19 ,  20 ]. Overall, 5-HT expression of all neurons in the enteric nervous system 
(ENS) reaches 2–20 % [ 21 ,  22 ]. 
 Research into 5-HT began in the ENS to accentuate the high concentrations of the 
neurotransmitter in this region, more specifi cally in the GI tract. Between 1937 and 
1940, the Italian researcher Vittorio Erspamer identifi ed a substance they called  enter-
amine , a “gut-stimulating factor” found in the mucosa of the intestine, later found to 
be 5-HT [ 23 ]. In the late 1940s a research group led by Page also purifi ed the same 
substance from beef blood, highlighting that it had vasoconstrictive activity. Page 
named this as “…  serotonin, which indicates that its source is serum and its activity is 
one of causing constriction …” [ 24 ]. Twarog and Page [ 25 ] performed a sensitive 
bioassay which used extracts of mammalian brain and detected 5-HT. Brodie and 
colleagues [ 26 ] suggested that 5-HT may serve as a neurotransmitter in the CNS, 
which was later supported further by the work of Costa and Aprison [ 27 ] who discov-
ered that it was in fact present in the human brain. This resulted in one of the most 
pivotal discoveries in science and the birth of a new branch of neuroscience [ 28 ]. 
 The serotonergic system has a topographical organisation corresponding to the 
functional and anatomical properties that they exhibit [ 29 ], and is one of the mam-
malian brain’s diffusively organised projective systems. The majority of serotonergic 
neurons reside in the brainstem, being particularly present in the raphe nuclei, part of 
the reticular formation. The 5-HT cells in this region are multipolar, with size and 
orientation being extremely different to other complex axonal systems in the 
CNS. They send projections virtually to all the CNS areas from limbic structures, 
basal ganglia, cerebral cortex and brainstem to the spinal cord grey matter. Upon the 
discovery that the brainstem contained these 5-HT cell groups, Dahlstrom and Fuxe 
[ 30 ] produced a system to code these groups based on the rat brainstem. These mor-
phologically heterogeneous cells have been divided into nine nuclei groups from B1 
(the most caudal cell cluster) to B9 (Fig.  14.1 ). These can then be combined into two 
major groups, the caudal and rostral serotonergic groups. The caudal group, also 
referred to as the inferior group, is situated in the medulla and consists of three sepa-
rate nuclei. These nuclei project to the grey matter of the spinal cord and are called the 
nucleus raphe magnus (NRM, group B5), the nucleus raphe obscures (NRO, groups 
B1, B2 and B3) and the nucleus raphe pallidus (NRP, group B4). The rostral group, 
also known as the superior group, is positioned in the pons/mesencephalon, and 
consists of two main nuclei: the fi rst being the dorsal raphe nucleus (DRN, groups B6 
and B7), which in the human brain is thought to contain about 235,000 neurons [ 31 ], 
and the second being the median raphe nucleus (MRN, cell group B8).
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2.1  Ascending Serotonergic Projections 
 The DRN and MRN are the main subdivisions of the raphe nucleus, providing 
innervation to nearly all structures of the CNS [ 32 – 37 ]. The primary targets of 5-HT 
projections lie in the forebrain and spinal cord, with the ascending projection col-
laterals reaching many different regions of the brain such as the cerebral cortex, 
basal ganglia, limbic system and diencephalon. These projections primarily travel in 
the medial forebrain bundle from which many axons extend toward other fi bre path-
ways in order to reach their target areas. Innervation patterns vary greatly between 
the different areas of the forebrain and are extremely specifi c. Fibre density in the 
cortex varies between layers; in primates the cortex receives a particularly dense 
5-HT innervation in layer IV [ 35 ,  38 ]. The striatum also has a very dense innerva-
tion, along with the hypothalamus, septal area and specifi c areas of the thalamus. 
 Most areas of the brain contain an overlapping innervation coming from the 
DRN and MRN, apart from the dorsal hippocampus, the suprachiasmatic nucleus, 
the olfactory bulb and the medial septum nucleus, which receive 5-HT innervation 
from only the MRN. On the other hand, the corpus striatum, the globus pallidus, the 
lateral septum nucleus, the amygdala and most of the prefrontal cortex (PFC) are all 
preferentially innervated by the DRN with the substantia nigra pars reticulata (SNr) 
receiving the largest DRN 5-HT innervation in the CNS [ 39 ,  40 ]. The ventral part of 
the hippocampus, the nucleus accumbens (NAcc) and various nuclei in the thalamus 
receive innervation from both the DRN and MRN [ 32 ]. Moreover, there are exten-
sive serotonergic connections between the two main serotonergic nuclei of the 
brainstem [ 41 ]. 
 Fig. 14.1  Midsagittal view of the rat brainstem with serotonin-immunoreactive cell body groups. 
The  ovals encompass the two major subdivisions of the brain serotonergic system.  DRN dorsal 
raphe nucleus,  MRN medial raphe nucleus,  NRM nucleus raphe magnus,  NRO nucleus raphe 
obscurus. Cell groups B1 to B9 according to the terminology of Dahlström and Fuxe [ 176 ] 
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 It is noteworthy that all the brain areas involved in drug addiction [ 33 ,  34 ,  37 ], 
such as the ventral tegmental area (VTA) and substantia nigra (SN), including 
their terminal fi elds, receive projections from 5-HT containing cell bodies in the 
raphe nuclei (Fig.  14.1 ) [ 34 ,  35 ,  42 ,  43 ], confi rming the implication of 5-HT in 
drug abuse. 
2.2  Descending Serotonergic Projections 
 Descending serotonergic projections to the spinal cord originate from the medullary 
raphe nuclear complex, forming a network of fi bres with a strong density of 5-HT 
axons throughout the grey matter [ 44 ]. More specifi cally, the dorsal horn, ventral 
horn motor nuclei and thoracic cord intermediolateral column have extremely dense 
serotonergic innervation. Additional regions receiving strong 5-HT input include 
the central grey matter and the ependyma of the central canal (containing a 5-HT 
nerve plexus). As highlighted above, the main origin of 5-HT afferents is the raphe 
nuclei, although other minor projections are also present. These are shown to origi-
nate from B9 cells scattered in the pontomesencephalic reticular area of the brain 
and also from cells in the medial longitudinal fasciculus [ 44 ,  45 ]. 
3  5-HT Receptors 
 The diversity of effects produced by 5-HT when administered in the brain is due to 
the large variety of receptors to which it binds. These are classifi ed into seven main 
classes, those being 5-HT 1 to 5-HT 7 . These are then further divided into 14 different 
receptor types, classifi ed by the means of pharmacological profi ling, cDNA-deduced 
primary sequencing and signal transduction methods [ 4 ,  5 ,  16 ,  46 ]. Most 5-HT 
receptors are metabotropic G-protein-coupled receptors (GPCRs), excluding the 
ionotropic 5-HT 3 receptors. The 5-HT GPCRs act through intracellular signalling 
pathways in order to depolarise or hyperpolarise their host cell [ 16 ]. 5-HT receptors 
may have synergistic or opposing activity. For example, in the administration of 
cocaine, blocking the 5-HT 2A receptors attenuated some of the effects of cocaine, 
whereas blocking the 5-HT 2C receptors caused an enhancement in some of the 
behavioural effects induced by cocaine [ 47 – 49 ]. The behavioural aspects linked to 
impulsivity are also mediated by the opposing actions of these two 5-HT 2 receptor 
subtypes [ 49 ]. It is of interest to note that the same 5-HT receptor subtypes located in 
different neuronal regions can act synergistically; that is, the 5-HT 1A receptors that 
are located both on raphe cell bodies and postsynaptically in limbic regions control 
impulse fl ow through the excitability of 5-HT raphe neurons and the postsynaptic 
neurons [ 50 ]. 
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4  Serotonergic Involvement in the CNS Effects of Nicotine 
 It has been suggested in several studies that 5-HT is one of the more important 
neurotransmitter systems involved in the reinforcing aspects of drugs of abuse [ 51 – 54 ]. 
The physiological and pharmacological effects of nicotine are complex. Interactions 
between nicotinic acetylcholine receptors (nAChRs), gamma-aminobutyric acid 
(GABA), glutamate (GLU) and DA in the VTA are involved in the reinforcing effects 
of nicotine (for reviews, see [ 55 ,  56 ] and Chap.  15 ). For instance, the activation of 
mesolimbic DA neurons is essential in the behavioural effects of nicotine, including 
locomotor activity and reinforcement [ 57 – 59 ]. 
 5-HT hypofunction is a defi ning factor in depression [ 60 ]. A number of animal 
and human studies suggest that changes in 5-HT transmission can contribute to the 
symptoms of nicotine withdrawal such as anxiety and depression [ 61 ] and an 
increased risk of suicide and self-harm [ 62 ]. Consistently, nicotine has been shown 
to manifest antidepressant effect on the user [ 63 ]; indeed prevalence of smoking is 
much higher amongst people suffering with depression [ 64 ]. 
 Previous studies into the molecular properties of nAChRs in the DRN have 
shown the presence of α4, α7 and β2 subunits [ 65 – 68 ]. The α7 subunit was found to 
be highly expressed on DRN neurons with a large diameter of 15–25 μm and colo-
calised with tryptophan hydroxylase [ 69 ]. It was also found on neurons with a 
smaller diameter of 5–10 μm that are usually GABAergic [ 66 ]. The cholinergic 
input to the serotonergic DRN cells is sustained by the pedunculopontine tegmen-
tum (PPTg) neurons [ 70 ]. In vitro electrophysiology studies have shown that the 
neuronal activity of 5-HT neurons is infl uenced by nicotine. Most 5-HT neurons of 
the DRN increase their action potential fi ring rate when nicotine is administered, 
which results in an overall increase in 5-HT output to its target tissues [ 71 – 73 ]. 
The excitability of these DRN neurons is also indirectly stimulated by their synaptic 
drive, which is infl uenced by nicotinic presynaptic heteroreceptors. Indeed, the 
effects of nicotine include the enhancement of excitatory glutamatergic input to 
DRN-NAcc projection neurons, and the positive or negative modulation of inhibi-
tory GABAergic input to the same subset. Nonetheless, in vivo systemic nicotine 
has been shown to decrease neuronal fi ring in the majority of DRN neurons, increas-
ing it in only a small subset of neurons [ 74 ,  75 ]. When nicotine was applied locally 
to the DRN it evoked 5-HT release [ 76 ], while systemic nicotine produced only a 
small and restricted increase in 5-HT [ 77 ]. Thus, the 5-HT fi ring inhibition may be 
a secondary effect, depending on 5-HT release from the somatic dendrites. Some 
in vivo data are in confl ict with in vitro results. It is important to consider that 5-HT 
neurons are strongly impacted by the arousal state (sleep-waking) [ 78 ]; therefore 
there is a possibility that the effects in the DRN neurons, upon nicotine administra-
tion in vivo, may be infl uenced by factors such as anaesthesia and the time of day that 
the experiment takes place. Moreover, acute exposure of DRN neurons to nicotine 
may therefore cause direct depolarisation and indirect synaptic modulation. Given 
the excitatory effects of nicotine on DRN neurons, it is likely that 5-HT contributes 
to the rewarding effects of nicotine. 
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 A number of the behavioural effects induced by nicotine may be mediated by the 
5-HT neurotransmitter system [ 61 ]. In this context, Summers and colleagues [ 79 ] 
showed that nicotine, as well as the nicotinic agonist RJR-2403, signifi cantly 
increased cortical release of 5-HT in rats. Since there has been no observation of 
nicotinic binding sites being present on 5-HT axon terminals in the cortex [ 80 ], the 
increased release of 5-HT might be due to the DRN projections to the cortex that 
express nAChRs in their soma [ 79 ]. 
 In addition, [ 3 H]5-HT release from striatal synaptosomes is increased by ACh, 
nicotine and the nicotinic receptor agonists epibatidine and cytosine; this effect can 
be inhibited by administration of the non-competitive nicotinic receptor antagonist 
mecamylamine [ 81 ]. The release of 5-HT into striatal slices due to nicotine expo-
sure showed an increase over a number of days; for example a signifi cant enhance-
ment after 10 days of nicotine treatment has been described [ 82 ]. Acute and chronic 
nicotine administration increased striatal 5-HT release in freely moving rats only 
when they were exposed to stress, likely by stimulating presynaptic nicotinic recep-
tors in the striatum [ 83 ]. Nicotinic receptor agonists such as 1,1-dimethyl-4- 
phenylpiperazinium (DMPP), lobeline and nicotine have been shown to increase 
[ 3 H]5-HT release in hippocampal slices in the rat; however cytisine, epibatidine and 
nicotine had no effect in others [ 84 ,  85 ]. Reuben and Clarke [ 81 ] also found sup-
porting evidence that nicotine had no effect on 5-HT release from the cerebral cor-
tex or hippocampal synaptosomes. Furthermore, there is confl icting evidence on the 
effects of chronic treatment with nicotine and the concentration of 5-HT in the 
dorsal hippocampus, with both decreases [ 86 ] and increases [ 87 ] being described. 
The duration of treatment is likely to be a factor in the effect of nicotine on the 
brain’s 5-HT system. Although, in one study, 5-HT levels in the hypothalamus 
increased following both acute and chronic nicotinic administration, rates of 5-HT 
synthesis were not affected [ 61 ]. 
 A number of pieces of research suggest that the release of 5-HT in the spinal 
cord is both directly and indirectly controlled through multiple nAChR populations. 
One nAChR population, located on 5-HT terminals, might have an excitatory effect 
on 5-HT outfl ow. Conversely, a second nAChR population, expressed on GABAergic 
interneurons and tonically activated by endogenous ACh, inhibits 5-HT release in 
the spinal grey matter [ 61 ]. 
 Nicotine is the main alkaloid found in nicotiana plants (95–97 %) and is largely 
responsible for the deleterious effects of tobacco including addiction. Two factors 
have to be taken into account when considering the mode of which nicotine is 
administered. First of all, a number of minor alkaloids are found in the plant (cotinine, 
anabasine, nornicotine, tabagisine, myosmine). These minor tobacco alkaloids have 
similar structural and pharmacological activity compared to nicotine, although they 
are generally less potent [ 88 ,  89 ]. Nornicotine and cotinine also play a role as major 
metabolites of nicotine [ 89 ]. Intravenous infusion of nicotine, combined with 
fi ve minor alkaloids found in tobacco smoke (anabasine, nornicotine, anatabine, 
cotinine and myosmine), increased locomotor activity and behavioural sensitisation 
following self-administration in rats [ 90 ]. A tobacco extract specifi cally containing 
nicotine and these alkaloids was more potent to enhancing striatal DA release in 
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freely moving rats compared to pure nicotine. The potentiation was not observed in 
the nucleus accumbens [ 91 ]. These experiments, using an extract, confi rm that the 
striatum plays an important role in the psychoactive properties of nicotine and/or 
tobacco (see below). Interestingly, the extract of alkaloids from the plant is more 
potent in inhibiting DRN neuronal fi ring rate compared to pure nicotine [ 75 ]. 
 Second, smoking tobacco generates a very high number of molecules (>4,000) 
that are absorbed which can also modulate the psychoactive properties of nicotine. 
It has been reported for instance that some of these compounds block the mono-
amine oxidases A and B (MAOA and MAOB), mitochondrial enzymes involved in 
the degradation of monoamines. These compounds may be relevant to tobacco 
addiction because their co-administration in rats has been shown to dramatically 
enhance the DA effects of nicotine and the motivation to self-administer nicotine 
[ 92 ]. The blockade of MAO-A and MAO-B, by limiting the degradation of 5-HT at 
the terminals, could favour 5-HT output and reinforce the dichotomy between the 
ability of nicotine to reduce DRN neuronal fi ring rate and to enhance 5-HT release 
at some terminals. However, this remains to be investigated. 
 On the whole, there is good supporting evidence from a number of sources to 
conclude that nicotine elicits an increase in 5-HT neuronal activity and an overall 
release of 5-HT in several target tissues in the brain including the DRN [ 76 ]. 
5  5-HT Receptors and the Rewarding Properties of Nicotine 
 In regard to the involvement of the various 5-HT receptor subtypes in nicotine use and 
dependence, very little work has been done to attribute the effects of administered 
ligands on these receptors, to the behavioural effects of nicotine. The 5-HT 1A , 
5-HT 2A , 5-HT 2C , 5-HT 3 , 5-HT 4 and 5-HT 6 subtypes are considered to be the most 
likely targets involved in nicotine use and dependence. In this chapter we focus on 
the 5-HT 2 receptor class. 
5.1  5-HT 2A Receptors 
 5-HT 2A receptors are the predominant receptor subtypes in cortical areas, but are 
also present in DA-rich areas such as the NAcc, striatum, VTA and SN [ 93 – 95 ]. 
Such receptors are situated mainly postsynaptically; for instance 5-HT 2A receptors 
are found on pyramidal neurons, as well as GABAergic interneurons in the PFC 
[ 96 ,  97 ]. 5-HT 2A receptors can also be found on DAergic and non-DAergic cells of 
the VTA and SN [ 97 – 99 ]. 5-HT 2A receptors are therefore seen, due to their anatomi-
cal distribution, as a good candidate for the modulation of DA-mediated functions. 
 A number of behavioural effects of nicotine are altered by 1-(2,5-dimethoxy- 4-
iodophenyl)-2-aminopropane (DOI) administration. For example, a study showed 
that DOI did not alter the acute stimulant action of nicotine, yet it did inhibit the 
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development of sensitisation to the locomotor stimulant effect when nicotine was 
administered repeatedly in rats [ 100 ]. When given to mice, DOI was shown to avert 
the initial locomotion suppression induced by nicotine [ 101 ]. DOI administration 
mitigated the discriminative stimulus properties of nicotine, effects that were 
inhibited by 5-HT 2A receptor antagonists, but not by 5-HT 2C receptor antagonists 
[ 101 ,  102 ]. These results provide evidence that 5-HT 2A receptor stimulation may 
oppose some of the behavioural effects of nicotine. Drug discrimination studies 
have shown a relationship between DOI and lysergic acid diethylamide (LSD) 
[ 103 ], with 5-HT 2A receptor stimulation by LSD and other drugs being recognised 
to induce hallucinations [ 104 ]. Even with this evidence, and although DOI can 
reduce some behavioural effects of nicotine, it is diffi cult to apply this to the treat-
ment of nicotine dependence in humans with 5-HT 2A receptor agonists. 5-HT 2A 
receptor blockade inhibits the extracellular increase of DA when induced by 
amphetamine and cocaine [ 105 ,  106 ]. This effect can also be seen on a behavioural 
level, in which the selective 5-HT 2A receptor antagonist M100907 attenuates loco-
motor stimulant effects of cocaine, amphetamine and other such psychomotor stim-
ulants [ 47 ,  48 ,  107 ]. The 5-HT 2A receptors resident in the VTA appear to be integral 
in modulating psychostimulant- induced behaviours mediated by the mesocorticoac-
cumbens circuit. Indeed local infusion of M100907 to the VTA blocked amphet-
amine- and cocaine-induced locomotion [ 47 ,  106 ]. Consistently, it has recently 
been shown that vulnerability of adult male rats to hyperactivity, induced by cocaine, 
is enhanced following virally mediated overexpression of 5-HT 2A receptors in the 
VTA [ 108 ]. Due to this evidence, and the relationship between the VTA and rein-
forcing effects of nicotine, it may be expected that 5-HT 2A receptor antagonists 
would modify some of the behavioural effects observed following the administra-
tion of nicotine. However, phasic but not tonic activation of 5-HT 2A receptors appear 
to have inhibitory infl uence on the nicotine cue, since their pharmacological stimu-
lation by DOI attenuates the discriminative stimulus effects of nicotine, while their 
blockade by M100907 was ineffective [ 102 ]. Recently, Levin and co-authors [ 109 ] 
showed that the 5-HT 2A/2C receptor antagonist, ketanserin, signifi cantly decreased 
nicotine self- administration. This effect is likely to be due to 5-HT 2C receptor 
blockade since, unlike ketanserin, the selective 5-HT 2A receptor antagonist M100907 
did not alter nicotine self-administration on the fi xed ratio schedule 5 (FR5) or 
progressive ratio schedules of reinforcement [ 110 ]. The reinstatement of nicotine-
seeking behaviour elicited by cues previously associated with self-administered 
nicotine or by priming injections of nicotine were both reduced by activation of 
5-HT 2C receptors and by blockade of 5-HT 2A receptors. 
 Collectively, these results show that while a 5-HT 2C receptor agonist and a 5-HT 2A 
receptor antagonist have differing effects on nicotine self-administration, they both 
reduce the reinstatement of nicotine-seeking behaviour [ 110 ]. This evidence shows 
that the reinforcing, psychomotor stimulant and discriminative effects of nicotine are 
not affected by 5-HT 2A receptor blockade, but that 5-HT 2A receptors may have a role 
in inducing nicotine-seeking behaviour. However, since M100907 reduced the rein-
statement of cocaine-seeking behaviour, induced by cocaine or cocaine-associated 
cues [ 110 ], it can be inferred that its effects are not nicotine specifi c. 
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5.2  5-HT 2C Receptors 
 5-HT has an infl uential role on the effects of many drugs of addiction and of particular 
interest is its action via the 5-HT 2C receptor subtype in modulating the effects of 
nicotine [ 1 ,  51 ,  54 ,  111 ]. 5-HT 2C receptors are located on DA cell bodies and 
GABAergic interneurons in the VTA area, observed by mapping studies [ 112 ,  113 ]. 
Furthermore, there is evidence that shows how central DA function is infl uenced by 
5-HT 2C receptors [ 10 ,  114 – 116 ], whereas blockage of the 5-HT 2A receptor has con-
sistently no effect on reinforcing the discriminative or the psychomotor stimulatory 
effects of nicotine. Administration of RO 60-0175, a selective 5-HT 2C receptor ago-
nist [ 117 ], in in vivo electrophysiological and neurochemical studies, induced a 
decrease in both the burst fi ring activity and basal fi ring rate of VTA DA neurons 
and decreased both striatal and accumbal DA release [ 118 – 121 ]. Moreover, the 
administration of the selective 5-HT 2C/2B receptor antagonist, SB 206553 [ 122 ], and 
the selective 5-HT 2C receptor antagonist, SB 242084 [ 123 ], both showed the oppo-
site effect on DA neuronal activity and DA release [ 115 ,  121 ,  124 ,  125 ]. Additionally, 
the use of RO 60-0175 to stimulate 5-HT 2C receptors in the VTA caused suppression 
of the stress-stimulated DA outfl ow in the rat PFC [ 126 ], whereas SB 242084 was 
found to potentiate it [ 126 ]. Alongside this, the phencyclidine-induced increase in 
accumbal DA release was enhanced by SB 242084 pretreatment [ 127 ]. Collectively, 
this evidence suggests that these receptors play a role in mediating the evoked DA 
release. In line with these studies, the increase in morphine-induced DA release in 
the NAcc was inhibited by stimulation of 5-HT 2C receptors in freely moving rats 
[ 96 ]. Furthermore, DA release in the NAcc and corpus striatum, in addition to 
the DA neuronal fi ring rate in the VTA and the substantia nigra pars compacta 
(SNc) induced by morphine, was enhanced by SB 206553 administration [ 128 ]. 
The effects of these agonists were blocked by SB 242084. The pharmacological 
stimulation of the 5-HT 2C receptor with RO 60-0175 and WAY163909 (another 
agonist of the 5-HT 2C receptor) has been shown to attenuate the discriminative 
stimulus effects induced by nicotine [ 102 ,  129 ]. SB 242084 alone induced some 
nicotine-induced responses (~30 %), although it did not alter the nicotine cue. Overall, 
these studies show that pharmacological stimulation of the 5-HT 2C receptors causes an 
attenuation of the discriminative stimulus response, although the tonic activation of 
these receptors does not infl uence the subjective effects of nicotine. 
 Investigations carried out by independent groups into the role of a 5-HT 2C 
receptor agonist, RO 60-0175, in nicotine self-administration, showed that on a 
fi xed- ratio/60-s timeout (FR5/ TO-60s) and FR5 schedule, RO 60-0175 caused a 
diminished response rate for nicotine [ 110 ,  130 ], and this effect was blocked by SB 
242084 [ 110 ]. Priming injections of nicotine were administered to induce reinstate-
ment of the response; this response was reduced by 5-HT 2C receptor agonism by RO 
60-0175 and lorcaserin (a relatively selective 5-HT 2C receptor agonist which has 
received the US Food and Drug Administration (FDA) approval as an anti-obesity 
drug) and by 5-HT 2A antagonism using M100907 [ 110 ,  131 ]. The observed dimin-
ished response rate for nicotine occurred over a similar range of doses to that 
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observed for cocaine self-administration [ 132 ], which was also reduced by 5-HT 2C 
manipulation [ 110 ,  132 – 134 ]. Moreover, the stimulation of 5-HT 2C receptors by 
RO 60-0175 reduced the previous nicotine-induced self-administration and 
nicotine- induced hyperactivity [ 130 ,  135 ]. In addition, a reduction in nicotine-
induced self- administration and hyperactivity was observed with ketanserin [ 109 ] 
and lorcaserin [ 136 ]. 
 Mixed results have been obtained from studies on nicotine-induced conditioned 
place preference involving the effects of 5-HT 2C receptor agonists such as RO 
60-0175, WAY161503 and WAY163909. In mice, RO 60-0175 blocked both 
nicotine- induced place preference and the conditioned place preference observed 
with tetrahydrocannabinol (THC) [ 137 ]. However, in rats, nicotine-induced place 
preference was not blocked by WAY161503, even at doses which induced locomo-
tion [ 138 ]. It is important to consider that the comparison of these studies is diffi cult, 
as it is unclear whether these discrepancies are due to the different 5-HT 2C receptor 
agonists or the different species on which they were carried out. 
 Interestingly RO 60-0175 was also able to block sensitisation to nicotine (occur-
ring after repeated exposure to the drug) as well as reduce nicotine-induced hyper-
locomotion and the operant response for nicotine [ 130 ]. Two separate studies using 
5-HT 2C agonists found that the stimulation of locomotion by nicotine in rats with 
prior nicotine exposure was blocked by both WAY161503 [ 138 ] and WAY163909 
[ 139 ], and furthermore that the administration of SB 242084 reinstated this effect of 
nicotine. 
 Two studies by Esposito and colleagues [ 140 ,  141 ] were conducted to investigate 
whether DA is involved in the behavioural effects of the interaction of RO 60-0175 
and nicotine-induced hyperlocomotion and reward. At 1 and 3 mg/kg doses of RO 
60-0175, the increase in DA release induced by the administration of acute nicotine 
was prevented in the corpus striatum but not in the NAcc [ 140 ]. However, enhanced 
DA release, induced by chronic nicotine administration, was prevented both in the 
corpus striatum and NAcc by the same doses of RO 60-0175 [ 140 ]. The selective 
5-HT 2C receptor antagonists, SB 242084 and SB243213, both inhibited the effects 
of RO 60-0175 [ 140 ]. At the doses used, it is probable that both SB 242084 and 
SB243213 specifi cally block 5-HT 2C receptors in the brain. Therefore, it can be 
inferred that blockage of the hyperlocomotive and rewarding effects of nicotine by RO 
60-0175 [ 132 ] are likely to be due to its ability to inhibit mesolimbic DA function. 
Differences in the effects of acute and repeated exposure to nicotine on the central 
5-HT system may explain why RO 60-0175 had varying effects on DA release in the 
NAcc, although further investigations are needed to elucidate this point. The effi -
cacy of the 5-HT 2C agonists could be indirect by acting against DA transmission 
within the basal ganglia. For instance, RO 60-0175 (1 mg/kg) has been shown to 
enhance the activity of GABAergic neurons of the VTA neurons [ 142 ] while DA 
transmission may favour their inhibition [ 143 ,  144 ]. Also, RO 60-0175 (1 mg/kg) 
enhanced the phasic and excitatory impact of the prefrontal but not the motor cortex 
stimulation on the activity of GABAergic neuron of the SNr [ 145 ]. The effi cacy of the 
5-HT 2C agonists could be more directly related to changes of DA indices especially 
because 5-HT 2C receptors control well an increase in DA release associated with an 
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increase in DA neuron fi ring rate [ 96 ,  128 ,  146 ]. Indeed, Pierucci et al. [ 141 ] tested 
the hypothesis that the effects seen in the NAcc and striatum with stimulation of 
5-HT 2C receptors and nicotine were due to changes in DA neuronal activity (see 
Figs.  14.2 ,  14.3 and  14.4 ). RO 60-0175 pretreatment prevented the enhancement in 
DA neuronal fi ring rate elicited by acute nicotine administration in the SNc, in both 
drug-naive and chronically treated rats, but was devoid of any signifi cant effect in 
the VTA. Moreover, RO 60-0175 signifi cantly reduced the stimulatory effect on the 
VTA DA neurons, induced by acute nicotine, both in drug-naive and chronically 
treated rats. However, after repeated administration of nicotine there were no 
changes observed in the nicotine-induced excitation of DA neurones in the VTA 
(see Figs.  14.3 and  14.4 ). Thus it seems that the chronic administration of nicotine 
does not potentiate the nicotine effect previously observed, via increasing the fi ring 
activity of mesolimbic DAergic neurons, but via another mechanism. Moreover, in 
rats previously treated with chronic nicotine, administration of acute nicotine caused 
a signifi cant increase in the burst fi ring activity of DA neurons in the VTA but not in 
the SNc [ 141 ]. It has been postulated that after repeated nicotine administration, 
tolerance to the stimulatory effect of nicotine occurs in the nigrostriatal but not in the 
mesolimbic DAergic system, a hypothesis also supported by the presented data.
 In further agreement, studies have recently revealed that there is a reduced 5-HT 
turnover and an increase in 5-HT 2C receptor sensitivity after the repeated adminis-
tration of nicotine. However the up-regulation of 5-HT 2C receptors is only observed 
following repeated treatment with this alkaloid. Furthermore, the expression of 
nicotine-induced locomotor sensitisation is counteracted by repeated administration 
of citalopram, a selective 5-HT re-uptake inhibitor [ 147 ]; therefore it can be hypoth-
esised that the development and expression of sensitisation to mesolimbic DA 
system, by repeated administration of nicotine, can be prevented by the activation 
of the 5-HT system. This effect could be benefi cial to smoking cessation therapies 
as the activation of the 5-HT system could lead to the extinction of nicotine-induced 
rewarding effect on the DAergic system. The activation of the 5-HT 2C receptors was 
previously associated with the effect of stimulating the GABAergic neurons which 
negatively impact on DA-containing neurons in the SNc and the VTA [ 1 ]; therefore 
it is speculated that the inhibitory action of RO 60-0175 on nicotine-induced DA 
release [ 140 ] and in the neuronal activity changes [ 141 ] might be also partially 
mediating this effect in a similar manner. Collectively, these results show that 
Fig. 14.2 (continued) nicotine administration on single DAergic neurons’ fi ring rates compared to 
controls (saline, 100 μl i.v., at  arrows ), while the graphs  below report the cumulative dose-response 
curves showing the mean percentage changes (±S.E.M.) in fi ring rate after either nicotine or saline 
administration.  Arrows indicate the time of nicotine or saline injections; apomorphine (Apo), a D1/
D2 receptor agonist, was injected (10–30 μg/kg, i.v.) at the end of most of the experiments to con-
fi rm the DAergic identity of recorded neurons (adapted from [ 141 ] with permission). ( b ) Time 
course of nicotine (1 mg/kg, i.p.)-induced effect on DA terminal release in both the striatum and 
nucleus accumbens. Changes in DA extracellular levels were assessed using in vivo microdialysis 
on freely moving animals. The  arrows indicate the time of injection of either nicotine or saline 
(adapted from [ 140 ] with permission) 
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 Fig. 14.2  Systemic administration of nicotine increases the activity of the both nigro-striatal and 
meso-corticolimbic DAergic systems of drug-naive rats in vivo. ( a ) The injection of cumulative 
doses of nicotine (25–775 μg/kg, i.v.) increased the fi ring rate of DA neurons recorded using 
in vivo single-unit extracellular recording technique. The rate meters on  top show the effect of 
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 Fig. 14.3  Systemic administration of nicotine increases the activity of both nigro-striatal and 
meso-corticolimbic DAergic systems in vivo of rats chronically treated with nicotine (1 mg/kg, 
i.p.) for 10 consecutive days. ( a ) The injection of cumulative doses of nicotine (25–775 μg/kg, i.v.)
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5-HT 2C receptor agonists reduce the stimulatory, discriminative and perhaps 
reinforcing effects of nicotine as well as reduce the impact of nicotine on electro-
physiological and neurochemical indices of DA function (Fig.  14.4 ). 
 The cessation of chronic nicotine use can produce aversive effects, including both 
motivational and somatic withdrawal symptoms such as nicotine craving, anxiety, 
reduced concentration, irritability, depressed mood and an increased appetite [ 148 ]. 
These withdrawal effects are considered to be the main factors in the  maintenance of 
the tobacco habit in human smokers. The role of 5-HT and the 5-HT 2C receptor in 
nicotine withdrawal and its negative effects is gradually being elucidated; recently it 
was shown that both RO 60-0175 and M100907 reversed the resultant depressive-like 
behaviour from nicotine withdrawal [ 149 ]. Conversely, preliminary results show that 
RO 60-0175 and lorcaserin do not reduce mecamylamine- precipitated somatic signs 
of withdrawal in nicotine-dependent rats [ 131 ]. 5-HT 2C drugs could be potentially 
benefi cial to relieve the aversive symptoms induced by nicotine cessation when 
combined with adjunct smoking cessation therapies. 
6  Smoking Cessation Treatment with the Use 
of Serotonergic Drugs 
 In the USA and Europe only approximately 6 % of those who quit smoking succeed 
in abstaining, despite 70 % of the population trying to quit at least once; therefore 
relapse is deemed to be the limiting factor in successful smoking cessation [ 150 ]. 
Half of relapses occur within 2 days of smoking cessation, and the majority occur 
within 3 months of quitting [ 151 ]. Environmental and sensory stimuli associated 
with smoking can act as conditioning stimuli which re-enforces smoking behaviour 
in humans [ 152 ]; in both active and former smokers the motivation to smoke can be 
increased on exposure to such cues (i.e. produce cue-induced craving) [ 153 ,  154 ]. 
All these factors are important considerations when generating the overall picture of 
smoking addiction. 
 Smoking is estimated to reduce the overall life expectancy of an individual by 
8 years and reduce the amount of “healthy” years by 12 [ 150 ]; therefore the devel-
opment of benefi cial therapies to facilitate smoking cessation and to reduce relapse 
Fig. 14.3 (continued) increased the fi ring rate of DA neurons recorded using in vivo single-unit 
extracellular recording technique. The rate meters on  top show the effect of nicotine administration 
on single DAergic neurons’ fi ring rates compared to controls (saline, 100 μl i.v., at  arrows ), while 
the graphs  below report the cumulative dose-response curves showing the mean percentage 
changes (±S.E.M.) in fi ring rate after either nicotine or saline administration.  Arrows indicate the 
time of nicotine or saline injections; apomorphine (Apo), a D1/D2 receptor agonist, was injected 
(10–30 μg/kg, i.v.) at the end of most of the experiments to confi rm the DAergic identity of recorded 
neurons (adapted from [ 141 ] with permission). ( b ) Time course of nicotine (1 mg/kg, i.p.)-induced 
effect on DA terminal release in both the striatum and nucleus accumbens. Changes in DA extracel-
lular levels were assessed using in vivo microdialysis on freely moving animals. The  arrows indicate 
the time of injection of either nicotine or saline (adapted from [ 140 ] with permission) 
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is of great interest. Nicotine replacement therapy (NRT) and the non-nicotine-based 
therapies are the two types of pharmacological interventions that have been approved 
by the US FDA for smoking cessation. NRT involves the replacement of nicotine 
with other nicotine-based formulations, which are less harmful than tobacco, in the 
 Fig. 14.4  Summary of evidence supporting a potential role for 5-HT 2C receptor agonists as treat-
ments for smoking cessation. ( a ) Effect of RO 60-0175 on hyperactivity induced by nicotine 
(0.4 mg/kg s.c), in rats previously sensitised to nicotine (ten daily injections of nicotine 0.4 mg/
kg s.c).  # p < 0.05 vs. vehicle/vehicle pretreatment, * p < 0.05 vs. vehicle/nicotine pretreatment. ( b ) 
Effect of RO 60-0175 on nicotine self-administration. Nicotine (0.03 mg/infusion) was available 
for 1 h each day, under an FR5TO 1-min schedule of reinforcement. ( c ) Effect of chronic treatment 
with vehicle, nicotine (0.4 mg/kg s.c) or nicotine (0.4 mg/kg s.c) + RO 60-0175 (1 mg/kg s.c) on 
locomotor activity produced by nicotine (0–0.4 mg/kg s.c). Prior nicotine exposure resulted in an 
enhanced locomotor response to nicotine (* p < 0.05) that was blocked by RO 60-0175 ( # p < 0.05). 
( d ) Time course of the effect of acute nicotine (1 mg/kg i.p.) on extracellular dopamine levels in 
the nucleus accumbens measured by microdialysis. Rats were treated for 10 days with nicotine 
(1 mg/kg i.p.) prior to the microdialysis experiment. Rats were treated with either vehicle or RO 
60-0175 (1 mg/kg i.p) 20 min before nicotine (1 mg/kg i.p) or vehicle (indicated by  arrow ). 
Nicotine increased extracellular dopamine release in the nucleus accumbens. This effect was sig-
nifi cantly attenuated by RO 60-0175 pretreatment. ( e ) Effect of nicotine (i.v.) and RO 60-0175 
(0.1 mg/kg i.v.) on the fi ring pattern of VTA dopamine neurons in rats treated for 10 days with 
nicotine (1 mg/kg i.p.). The data represent the mean ± SEM difference between the percentages of 
spikes occurring in bursts during baseline vs. post-drug periods. The data show that nicotine 
increases burst fi ring of VTA dopamine neurons, and that this effect is blocked by RO 60-0175. 
Figure reproduced from [ 53 ] with permission 
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form of chewing gum, transdermal patches or inhalers [ 155 ]. Non-nicotine-based 
therapy is represented mostly by bupropion, an atypical antidepressant [ 156 ,  157 ], 
or varenicline, the α4β2* nAChR partial agonist [ 158 ]. Comparing these therapies, 
NRTs have proved to be the least effective for smoking cessation, with varenicline 
being the most effective, followed by bupropion [ 159 ]. The increased effi cacy of 
varenicline is likely to be due to its ability to both aid smoking cessation and prevent 
relapse; varenicline partially activates the α4β2* nAChRs (also activated by smoking); 
therefore when paired with smoking cessation it effectively mimics the effects of 
smoking and, additionally, if a relapse occurs varenicline prevents the full activation 
of α4β2* nAChRs [ 160 ]. 
 Bupropion was the fi rst non-NRT to be used for smoking cessation, although it 
later appeared to be a non-competitive antagonist of several nAChRs. The 
 sustained- release bupropion formulation, the phenylaminoketone atypical antide-
pressant agent, was approved in the USA in 1997 by the FDA. It is thought that the 
ability of bupropion to block DA and noradrenaline (NA) reuptake, although mod-
estly, accounts for its ability to treat nicotine dependence, but its exact mechanism 
of action is still unclear [ 156 ]. Moreover, the clinical effi cacy of bupropion as a 
smoking cessation aid may be due to its antagonistic activity at nAChRs [ 161 ]. 
Threohydroxybupropion and hydroxybupropion are the major metabolites of bupro-
pion, and they inhibit DA and NA reuptake to the same or lesser extent as bupropion 
[ 156 ]. Bupropion and hydroxybupropion administered in a dose-dependent manner 
were found to reduce the fi ring rate of noradrenergic neurons in the locus coeruleus, 
similar to tricyclic antidepressants (TCAs); the α 2 -adrenergic antagonist yohimbine 
reversed this action [ 162 ]. In vitro, bupropion diminished the tonic inhibition of DA 
neurones via a reduction in the GABAergic transmission to these neurones, and also 
greatly reduced the effects of nicotine on DA neuron excitability [ 163 ]. The antide-
pressant action of bupropion may be aided, in the absence of nicotine, by these 
increases in DA neuron excitability during treatment [ 163 ]. Overall, this suggests 
that the antidepressant effect of bupropion may be partially due to a DAergic or a 
noradrenergic counterpart. Additionally, in the DRN, bupropion caused a sustained 
increase in the basal fi ring activity of 5-HT neurons [ 164 ], but currently the signifi -
cance of the mechanism of action of bupropion in this latter effect, in a clinical 
setting, is unknown. 
 Varenicline, its trade name being Chantix in the USA and Champix in Canada, 
Europe and other countries, was developed by Pfi zer and introduced as a novel 
smoking cessation aid with a high effi cacy for the α4β2 nAChR, in 2006 [ 158 ,  160 ]. 
Varenicline affects monoaminergic neurotransmission by modulating release of DA, 
NA and 5-HT. Varenicline selectively binds to α4β2* nAChRs with high affi nity, 
similar to nicotine-evoked DA release in the rat NAcc due to its interaction with 
α4β2* nAChRs in the VTA [ 158 ,  160 ,  165 ]. Varenicline competitively blocks nico-
tine from binding to the nAChRs, and thus stimulates the mesolimbic DA system. 
 In the rat, only high doses of varenicline (10 mg/kg) produce increases in PFC DA 
and NA release [ 166 ], whereas 1 mg/kg produces no signifi cant changes in extracel-
lular levels of 5-HT, NA and DA [ 167 ]. The effect of a 10 mg/kg dose, that is associ-
ated with very high brain concentrations of >1 μM, may be due to the interaction of 
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varenicline with several other nAChR subtypes other than α4β2 nAChRs. Varenicline 
has a very low affi nity for 5-HT receptors and the 5-HT transporter; its lack of inter-
action with central 5-HT receptors and its inability to block 5-HT reuptake mean it 
is unable to increase 5-HT; thus its  in vitro properties explain why it has little effect on 
cortical monoamine release. Varenicline is also a full agonist of 5-HT 3A receptors; 
however, despite having a modest affi nity for these receptors, the brain concentra-
tions of therapeutic unbound varenicline are hypothesised to be insuffi cient to 
activate central 5-HT 3A receptors. Moreover varenicline does not inhibit MAO-A, 
the enzyme which metabolises 5-HT, and does not bind to DA receptors that modu-
late 5-HT release. Additionally, when varenicline is combined with one or both 
antidepressant drugs it did not cause signifi cant effects on the increased neurotrans-
mitter levels, induced by sertraline and/or clorgyline [ 167 ]. Despite the fi ndings that 
varenicline is more effective than bupropion and NRT in recent meta-analyses 
[ 159 ,  168 ], there was an observed increase in neuropsychiatric symptoms in those 
taking varenicline, causing the FDA to issue an alert [ 169 ]. These neuropsychiatric 
symptoms include behavioural changes, agitation, depressed mood, hostility and 
suicidal thoughts. This has led to a large clinical trial to reassess the safety of 
varenicline, evaluating the neuropsychiatric adverse events; this is expected to be 
complete by 2017. Nevertheless, a recent prospective cohort study showed that 
there is no evidence of an increased risk of suicidal behaviour in patients pre-
scribed varenicline or bupropion compared with those prescribed nicotine replace-
ment therapy [ 62 ]. These fi ndings should be reassuring for users and prescribers of 
smoking cessation medicines. 
 Antidepressants are the most common drug, in the class of non-nicotine-based 
drugs, to be effective in aiding smoking cessation. TCAs which inhibit NA and 5-HT 
such as nortriptyline [ 170 – 172 ] and doxepin [ 173 ] have been proposed to be of 
benefi t in aiding smoking cessation, in combination with behavioural treatment. 
 Due to the primary role of 5-HT in the modulation of smoking behaviour and 
nicotine reward, selective serotonin reuptake inhibitors (SSRIs) have been studied as 
a safer and better tolerated antidepressant to TCAs. Indeed, anticholinergic activity 
and frequent lethality in overdose are associated with TCAs; thus these signifi cant 
aversive side effects mean other substances are being targeted for the benefi cial ther-
apeutic use [ 61 ,  111 ]. Fluoxetine, a prototypical SSRI, was shown to have equivocal 
results to TCAs and may relieve most of the adverse withdrawal symptoms experi-
enced by smokers with a history of depression [ 174 ]. The 5-HT 1A receptor is involved 
in anxiolytic activity; therefore buspirone, a 5-HT 1A receptor partial agonist, has been 
studied for its use as an anti-anxiolytic in order to treat nicotine addiction. Buspirone 
administration stimulates the 5-HT 1A receptors leading to a reduction in presynaptic 
release of 5-HT, which appears to mediate anxiolytic effects. Unfortunately buspi-
rone was shown to have little effect in aiding smoking cessation, shown by a placebo-
controlled clinical trial [ 175 ]. 5-HT 2C receptor agonists could also potentially be 
utilised for the treatment of smoking cessation [ 49 ,  111 ,  129 ]. Weight gain is viewed 
as a contributory factor in preventing smoking cessation; therefore the role of 5-HT 2C 
receptor agonists in decreasing feeding behaviour and thus preventing weight gain 
could be of particular interest in benefi cially treating nicotine dependence [ 176 ] 
(Table  14.1 ).
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 Doses of lorcaserin that reduce feeding behaviour and behavioural effects 
induced by nicotine in rats [ 131 ] result in plasma levels similar to those observed in 
people taking a therapeutic dose of lorcaserin for obesity [ 111 ], thus suggesting that 
dose regimens used in obesity treatment would be appropriate for testing lorcaserin 
in a smoking-cessation trial. However one disadvantage of using this drug is its 
potential interaction with 5-HT 2A receptors, thought to induce hallucinogenic 
effects. Moreover, it is as of yet unknown to what extent lorcaserin, along with other 
5-HT 2C agonists, occupies and activates the 5-HT 2C receptors at therapeutic expo-
sure. However, due to lorcaserin being the fi rst 5-HT 2C receptor agonist with clinical 
approval, it is a preferable and viable method for the application of testing animal 
evidence in humans [ 111 ]. 
7  Conclusions 
 Nicotine exerts a wide range of effects on multiple neurotransmitter systems including 
ACh, GLU, DA, NA, 5-HT and GABA by acting on nAChRs; it is considered to be 
an extraordinary psychotropic drug as it is diffi cult to fi nd another with such a pleio-
tropic action. The 5-HT pathway is implicated in nicotine dependence and may 
infl uence smoking cessation; the 5-HT 2C receptor seems to be the most likely receptor 
to be involved. 
 The pharmacotherapy of nicotine addiction is still considered to be unsatisfac-
tory, despite a large amount of data being produced on the neurobiological basis of 
withdrawal, action and dependence of nicotine. An increasing body of evidence has 
indicated that 5-HT 2C neurotransmission is a critical neurological substrate in the 
process of smoking cessation or its role in the suppression of nicotine withdrawal in 
smokers. 5-HT 2C receptor agonists could be useful in treating not only the wide 
 Table 14.1  Effects of varenicline, bupropion, RO 60-0175 and lorcaserin against various nicotine- 
motivated behaviours in the rodent (adapted from [ 111 ] with permission) 
 Varenicline  Bupropion  RO 60-0175  Lorcaserin 
 Nicotine self-administration  ↓  ↔  ↓  ↓ 
 Nicotine-induced hyperlocomotion  ↓  ↔  ↓  ↓ 
 Nicotine interoceptive cue  ↑/↓  ↔  ↓  ↓ 
 Reinstatement of nicotine-seeking 
behavioura 
 ↓  ↔  ↓  ↓ 
 Nicotine-conditioned place preference  ↓  ↑  NT  NT 
 Nicotine-precipitated W/D b (somatic)  NT  ↓  ↔  ↔ 
 Nicotine-precipitated W/D (affective)  NT  ↓  ↓  NT 
 ↓, Reduced response; ↑, increased response; ↔, no reliable effect; ↑/↓, mixed effects reported; 
NT = not tested 
 a In the case of varenicline, bupropion and lorcaserin, each was assessed against reinstatement 
produced by a combination of nicotine prime and cues. RO 60-0175 was shown to be effective 
against reinstatement induced by either a nicotine prime or cues 
 b W/D withdrawal/dependence 
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range of behaviours produced by nicotine addiction, but also other drugs of abuse, 
because of the widespread infl uence of these receptors on behaviour. In conclusion, 
a more complete preclinical evaluation of the 5-HT 2C receptor role in nicotine addic-
tion will ultimately allow educated, proof-of-concept trials to test the concept that 
selective 5-HT 2C agonists such as lorcaserin may be useful as adjunctive therapy. 
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